<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34023008</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-547X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>397</Volume>
            <Issue>10290</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Lancet (London, England)</Title>
          <ISOAbbreviation>Lancet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.</ArticleTitle>
        <Pagination>
          <StartPage>2151</StartPage>
          <EndPage>2168</EndPage>
          <MedlinePgn>2151-2168</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(21)00588-2</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(21)00588-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis.</AbstractText>
          <AbstractText Label="METHODS">Measure Up 1 and Measure Up 2 were replicate multicentre, randomised, double-blind, placebo-controlled, phase 3 trials; Measure Up 1 was done at 151 clinical centres in 24 countries across Europe, North and South America, Oceania, and the Asia-Pacific region; and Measure Up 2 was done at 154 clinical centres in 23 countries across Europe, North America, Oceania, and the Asia-Pacific region. Eligible patients were adolescents (aged 12-17 years) and adults (aged 18-75 years) with moderate-to-severe atopic dermatitis (≥10% of body surface area affected by atopic dermatitis, Eczema Area and Severity Index [EASI] score of ≥16, validated Investigator's Global Assessment for Atopic Dermatitis [vIGA-AD] score of ≥3, and Worst Pruritus Numerical Rating Scale score of ≥4). Patients were randomly assigned (1:1:1) using an interactive response technology system to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily for 16 weeks, stratified by baseline disease severity, geographical region, and age. Coprimary endpoints were the proportion of patients who had achieved at least a 75% improvement in EASI score from baseline (EASI-75) and the proportion of patients who had achieved a vIGA-AD response (defined as a vIGA-AD score of 0 [clear] or 1 [almost clear] with ≥2 grades of reduction from baseline) at week 16. Efficacy was analysed in the intention-to-treat population and safety was analysed in all randomly assigned patients who received at least one dose of study drug. These trials are registered with ClinicalTrials.gov, NCT03569293 (Measure Up 1) and NCT03607422 (Measure Up 2), and are both active but not recruiting.</AbstractText>
          <AbstractText Label="FINDINGS">Between Aug 13, 2018, and Dec 23, 2019, 847 patients were randomly assigned to upadacitinib 15 mg (n=281), upadacitinib 30 mg (n=285), or placebo (n=281) in the Measure Up 1 study. Between July 27, 2018, and Jan 17, 2020, 836 patients were randomly assigned to upadacitinib 15 mg (n=276), upadacitinib 30 mg (n=282), or placebo (n=278) in the Measure Up 2 study. At week 16, the coprimary endpoints were met in both studies (all p&lt;0·0001). The proportion of patients who had achieved EASI-75 at week 16 was significantly higher in the upadacitinib 15 mg (196 [70%] of 281 patients) and upadacitinib 30 mg (227 [80%] of 285 patients) groups than the placebo group (46 [16%] of 281 patients) in Measure Up 1 (adjusted difference in EASI-75 response rate vs placebo, 53·3% [95% CI 46·4-60·2] for the upadacitinib 15 mg group; 63·4% [57·1-69·8] for the upadacitinib 30 mg group) and Measure Up 2 (166 [60%] of 276 patients in the upadacitinib 15 mg group and 206 [73%] of 282 patients in the upadacitinib 30 mg group vs 37 [13%] of 278 patients in the placebo group; adjusted difference in EASI-75 response rate vs placebo, 46·9% [39·9-53·9] for the upadacitinib 15 mg group; 59·6% [53·1-66·2] for the upadacitinib 30 mg group). The proportion of patients who achieved a vIGA-AD response at week 16 was significantly higher in the upadacitinib 15 mg (135 [48%] patients) and upadacitinib 30 mg (177 [62%] patients) groups than the placebo group (24 [8%] patients) in Measure Up 1 (adjusted difference in vIGA-AD response rate vs placebo, 39·8% [33·2-46·4] for the upadacitinib 15 mg group; 53·6% [47·2-60·0] for the upadacitinib 30 mg group) and Measure Up 2 (107 [39%] patients in the upadacitinib 15 mg group and 147 [52%] patients in the upadacitinib 30 mg group vs 13 [5%] patients in the placebo group; adjusted difference in vIGA-AD response rate vs placebo, 34·0% [27·8-40·2] for the upadacitinib 15 mg group; 47·4% [41·0-53·7] for the upadacitinib 30 mg group). Both upadacitinib doses were well tolerated. The incidence of serious adverse events and adverse events leading to study drug discontinuation were similar among groups. The most frequently reported treatment-emergent adverse events were acne (19 [7%] of 281 patients in the upadacitinib 15 mg group, 49 [17%] of 285 patients in the upadacitinib 30 mg group, and six [2%] of 281 patients in the placebo group in Measure Up 1; 35 [13%] of 276 patients in the upadacitinib 15 mg group, 41 [15%] of 282 patients in the upadacitinib 30 mg group, and six [2%] of 278 patients in the placebo group in Measure Up 2), upper respiratory tract infection (25 [9%] patients, 38 [13%] patients, and 20 [7%] patients; 19 [7%] patients, 17 [16%] patients, and 12 [4%] patients), nasopharyngitis (22 [8%] patients, 33 [12%] patients, and 16 [6%] patients; 16 [6%] patients, 18 [6%] patients, and 13 [5%] patients), headache (14 [5%] patients, 19 [7%] patients, and 12 [4%] patients; 18 [7%] patients, 20 [7%] patients, and 11 [4%] patients), elevation in creatine phosphokinase levels (16 [6%] patients, 16 [6%] patients, and seven [3%] patients; nine [3%] patients, 12 [4%] patients, and five [2%] patients), and atopic dermatitis (nine [3%] patients, four [1%] patients, and 26 [9%] patients; eight [3%] patients, four [1%] patients, and 26 [9%] patients).</AbstractText>
          <AbstractText Label="INTERPRETATION">Monotherapy with upadacitinib might be an effective treatment option and had a positive benefit-risk profile in adolescents and adults with moderate-to-severe atopic dermatitis.</AbstractText>
          <AbstractText Label="FUNDING">AbbVie.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guttman-Yassky</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teixeira</LastName>
            <ForeName>Henrique D</ForeName>
            <Initials>HD</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simpson</LastName>
            <ForeName>Eric L</ForeName>
            <Initials>EL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papp</LastName>
            <ForeName>Kim A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Probity Medical Research, Waterloo, ON, Canada; K Papp Clinical Research, Waterloo, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pangan</LastName>
            <ForeName>Aileen L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blauvelt</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Oregon Medical Research Center, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thaçi</LastName>
            <ForeName>Diamant</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chu</LastName>
            <ForeName>Chia-Yu</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>H Chih-Ho</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Probity Medical Research, Waterloo, ON, Canada; Dr Chih-ho Hong Medical, Surrey, BC, Canada; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Katoh</LastName>
            <ForeName>Norito</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paller</LastName>
            <ForeName>Amy S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calimlim</LastName>
            <ForeName>Brian</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Yihua</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Xiaofei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tenorio</LastName>
            <ForeName>Allan R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chu</LastName>
            <ForeName>Alvina D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Irvine</LastName>
            <ForeName>Alan D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Medicine, Trinity College Dublin, University of Dublin, Dublin, Ireland; Wellcome-HRB Clinical Research Facility, St James' Hospital, Dublin, Ireland. Electronic address: irvinea@tcd.ie.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03607422</AccessionNumber>
              <AccessionNumber>NCT03569293</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Lancet</MedlineTA>
        <NlmUniqueID>2985213R</NlmUniqueID>
        <ISSNLinking>0140-6736</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4RA0KN46E0</RegistryNumber>
          <NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C507904">JAK1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Lancet. 2021 Jun 5;397(10290):2126-2128</RefSource>
          <PMID Version="1">34023007</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Lancet. 2021 Jun 5;397(10290):2150</RefSource>
          <PMID Version="1">34090603</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003876" MajorTopicYN="N">Dermatitis, Atopic</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="Y">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053613" MajorTopicYN="N">Janus Kinase 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Declaration of interests EG-Y is employed by Mount Sinai and is a researcher or consultant for AbbVie, Anacor, AnaptysBio, Asana Biosciences, Botanix, Celgene, DBV, Dermira, Dr Reddy's Laboratory (Promius), DS Biopharma, Escalier Biosciences, Galderma, Glenmark, Innovaderm, Janssen, Kyowa Kirin, LEO Pharma, Lilly, AstraZeneca, Mitsubishi Tanabe Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron, Sanofi, GlaxoSmithKline, UCB, and Vitae Pharmaceuticals. HDT, ALP, BC, YG, XH, ML, YY, JL, ART, and ADC are full-time employees of AbbVie, and might hold AbbVie stock or stock options. ELS reports grants, personal fees, and non-financial support from Lilly; grants and personal fees from Anacor, Bausch Health (Valeant), GlaxoSmithKline, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi Genzyme; personal fees from AbbVie, Celgene, Dermira, Galderma, Genentech, LEO Pharma, and Menlo Therapeutics; and grants from MedImmune, Novartis, Roivant, Tioga Pharmaceuticals, and Vanda. KAP is an adviser, speaker, consultant, and steering committee member or researcher for AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, AstraZeneca, Bausch Health (Valeant), Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite, Celgene, Coherus, Dermira, Dow, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, InflaRx, Janssen, Kyowa Kirin, LEO Pharma, Lilly, MedImmune, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Moberg Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, and UCB. AB has served as a scientific adviser or clinical study investigator for AbbVie, Almirall, Arena Pharmaceuticals, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Forté Pharma, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; and is a paid speaker for AbbVie. DT is an advisor, speaker, or consultant for AbbVie, Almirall, Amgen, Asana Biosciences, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DS Biopharma, Janssen, Kyowa Kirin, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, and UCB; and is also involved in research for AbbVie, Celgene, LEO Pharma, and Novartis. C-YC is an investigator for AbbVie, Dermira, Lilly, Novartis, Oneness Biotech, Pfizer, Regeneron, Roche, and Sanofi; a consultant for AbbVie, Lilly, Novartis, Pfizer, Roche, and Sanofi; a speaker for AbbVie, Lilly, Mylan, Novartis, Pfizer, Roche, and Sanofi; and an advisory board member for Mylan, Pfizer, Roche, and Sanofi. HCH is a researcher, consultant, or advisor for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Dermira, Dermavant, DS Biopharma, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, and UCB. NK has received honoraria as a speaker or consultant for AbbVie, Janssen, LEO Pharma, Lilly, Maruho, Mitsubishi Tanabe Pharma, Sanofi, and Taiho Pharmaceutical, and has received grants as an investigator from AbbVie, Kyowa Kirin, LEO Pharma, Lilly, Maruho, Mitsubishi Tanabe Pharma, and Sanofi. ASP has served as an investigator for AbbVie, Anaptysbio, Incyte, Janssen, LEO Pharma, Lilly, Lenus, Novartis, Regeneron, and UCB, and received honorarium for consultancy from AbbVie, Abeona, Almirall, Asana Biosciences, Boehringer Ingelheim, Bridgebio, Dermavant, Dermira, Exicure, Forte Pharma, Galderma, Incyte, InMed, Janssen, LEO Pharma, Lilly, LifeMax, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Sanofi Genzyme, Sol-Gel, and UCB. ADI has received honorarium for consultancy from AbbVie, Arena Pharmaceuticals, BenevolentAI, Chugai, Dermavant, Genentech, LEO Pharma, Lilly, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sanofi, and UCB.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34023008</ArticleId>
        <ArticleId IdType="doi">10.1016/S0140-6736(21)00588-2</ArticleId>
        <ArticleId IdType="pii">S0140-6736(21)00588-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
